El medicamento innovador para vencer la adicción: ¿Ozempic?news2024-11-06T10:40:06+00:00November 6th, 2024|The New York Times|
From AI to Musk’s Brain Chip, the F.D.A.’s Device Unit Faces Rapid Changenews2024-11-01T23:57:56+00:00November 1st, 2024|The New York Times|
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trialsnews2024-10-23T14:19:56+00:00October 23rd, 2024|The New York Times|
Why We May Soon Use Ozempic to Treat Addictionnews2024-10-18T12:20:09+00:00October 18th, 2024|The New York Times|
FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’snews2024-07-02T18:58:44+00:00July 2nd, 2024|The New York Times|
Hace casi un año se aprobó un fármaco para frenar el alzhéimer. ¿Ha funcionado?news2024-06-17T21:59:44+00:00June 17th, 2024|The New York Times|
FDA Advisory Panel Endorses Approval of Alzheimer’s Drug Made by Eli Lillynews2024-06-10T21:05:19+00:00June 10th, 2024|The New York Times|
Leqembi and Alzheimer’s: What to Know About the New Drug, Treatment and Benefitsnews2024-06-10T09:00:35+00:00June 10th, 2024|The New York Times|
Ozempic Is Repairing a Hole in Our Diets Created by Processed Foodsnews2024-05-07T11:01:48+00:00May 7th, 2024|The New York Times|
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snews2024-05-06T16:19:15+00:00May 6th, 2024|The New York Times|
